Morgana acts as an oncosuppressor in chronic myeloid leukemia

Blood

Volumn 125, Issue 14, 2015, Pages 2245-2253

  Di Savino, Augusta ^a   Panuzzo, Cristina ^b   Rocca, Stefania ^a   Familiari, Ubaldo ^b   Piazza, Rocco ^c   Crivellaro, Sabrina ^b   Carrà, Giovanna ^b   Ferretti, Roberta ^a   Fusella, Federica ^a   Giugliano, Emilia ^b   Camporeale, Annalisa ^a   Franco, Irene ^a   Miniscalco, Barbara ^d   Cutrin, Juan Carlos ^a   Turco, Emilia ^a   Silengo, Lorenzo ^a   Hirsch, Emilio ^a   Rege Cambrin, Giovanna ^b   Gambacorti Passerini, Carlo ^c   Pandolfi, Pier Paolo ^a,e   Papotti, Mauro ^b   Saglio, Giuseppe ^b   Tarone, Guido ^a   Morotti, Alessandro ^b   Brancaccio, Mara ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Clinical Medicine Section   (Italy)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; ENZYME; IMATINIB; MORGANA; PROTEIN; PROTEIN KINASE B; ROCK I KINASE; ROCK II KINASE; STAT5 PROTEIN; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CARRIER PROTEIN; CHP-1 PROTEIN, MOUSE; MESSENGER RNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RHO KINASE;

APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CENTROSOME; CHRONIC MYELOID LEUKEMIA; DRUG RESPONSE; FLOW CYTOMETRY; HAPLOINSUFFICIENCY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW; C57BL MOUSE; CELL PROLIFERATION; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; BONE MARROW; CARRIER PROTEINS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84926658332     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-575001     Document Type: Article

References (49)

1. Perl A, Carroll M. BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest. 2011;121(1):22-25.
2. Redner RL. Why doesn't imatinib cure chronic myeloid leukemia? Oncologist. 2010;15(2):182-186.
3. Morotti A, Panuzzo C, Fava C, Saglio G. Kinaseinhibitorinsensitive cancer stem cells in chronic myeloid leukemia. Expert Opin Biol Ther. 2014;14(3):287-299.
4. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18-24.
5. Guo-yu H, Chao-hui Y, Kui T, Zhen-zhen C. Atypical chronic myeloid leukaemia with trisomy 13: a case report. Chin Med Sci J. 2011;26(4):254-256.
6. Hernández JM, del Cañizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11(4):441-444.
7. Burgstaller S, Reiter A, Cross NC. BCR-ABLnegative chronic myeloid leukemia. Curr Hematol Malig Rep. 2007;2(2):75-82.
8. Ferretti R, Palumbo V, Di Savino A, et al. Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. Dev Cell. 2010;18(3):486-495.
9. Hanashiro K, Brancaccio M, Fukasawa K. Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification. Oncogene. 2011;30(19):2188-2197.
10. Ferretti R, Sbroggiò M, Di Savino A, et al. Morgana and melusin: two fairies chaperoning signal transduction. Cell Cycle. 2011;10(21):3678-3683.
11. Fukasawa K. Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer. 2007;7(12):911-924.
12. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009;460(7252):278-282.
13. Crasta K, Ganem NJ, Dagher R, et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature. 2012;482(7383):53-58.
14. Fusella F, Ferretti R, Recupero D, et al. Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway. J Pathol. 2014;234(2):152-163.
15. Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9(5):e96801.
16. Gavrilescu LC, Van Etten RA. Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders. In: Enna SJ, ed. Current protocols in pharmacology. New York, NY: Wiley; 2008:14-10.
17. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453(7198):1072-1078.
18. Kaufmann KB, Gründer A, Hadlich T, et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med. 2012;209(1):35-50.
19. Kogan SC, Ward JM, Anver MR, et al; Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100(1):238-245.
20. Saglio G, Storlazzi CT, Giugliano E, et al. A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation. Proc Natl Acad Sci USA. 2002;99(15):9882-9887.
21. Patel H, Gordon MY. Abnormal centrosomecentriole cycle in chronic myeloid leukaemia? Br J Haematol. 2009;146(4):408-417.
22. Krämer A. Centrosome aberrations-hen or egg in cancer initiation and progression? Leukemia. 2005;19(7):1142-1144.
23. Giehl M, Fabarius A, Frank O, et al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia. 2005;19(7):1192-1197.
24. Mali RS, Ramdas B, Ma P, et al. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011;20(3):357-369.
25. Kuzelová K, Hrkal Z. Rho-signaling pathways in chronic myelogenous leukemia. Cardiovasc Hematol Disord Drug Targets. 2008;8(4):261-267.
26. Burthem J, Rees-Unwin K, Mottram R, et al. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34 (+) CML progenitor cells. Leukemia. 2007;21(8):1708-1714.
27. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 2006;10(5):425-435.
28. Li Z, Dong X, Wang Z, et al. Regulation of PTEN by Rho small GTPases. Nat Cell Biol. 2005;7(4):399-404.
29. Vemula S, Shi J, Hanneman P, Wei L, Kapur R. ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood. 2010;115(9):1785-1796.
30. Warsch W, Kollmann K, Eckelhart E, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117(12):3409-3420.
31. Shirasu K, Lahaye T, Tan MW, Zhou F, Azevedo C, Schulze-Lefert P. A novel class of eukaryotic zinc-binding proteins is required for disease resistance signaling in barley and development in C. elegans. Cell. 1999;99(4):355-366.
32. Brancaccio M, Menini N, Bongioanni D, et al. Chp-1 and melusin, two CHORD containing proteins in vertebrates. FEBS Lett. 2003;551(1-3):47-52.
33. Hahn JS. Regulation of Nod1 by Hsp90 chaperone complex. FEBS Lett. 2005;579(20):4513-4519.
34. Wu J, Luo S, Jiang H, Li H. Mammalian CHORDcontaining protein 1 is a novel heat shock protein 90-interacting protein. FEBS Lett. 2005;579(2):421-426.
35. Michowski W, Ferretti R, Wisniewska MB, et al. Morgana/CHP-1 is a novel chaperone able to protect cells from stress. Biochim Biophys Acta. 2010;1803(9):1043-1049.
36. Holland AJ, Cleveland DW. Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements. Nat Med. 2012;18(11):1630-1638.
37. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet. 2012;13(3):189-203.
38. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645-2651.
39. Muramatsu H, Makishima H, Maciejewski JP. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol. 2012;39(1):67-73.
40. Cazzola M, Malcovati L, Invernizzi R. Myelodysplastic/myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program. 2011;2011:264-272.
41. Kosmider O, Gelsi-Boyer V, Ciudad M, et al; Groupe Francophone des Myélodysplasies. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676-1681.
42. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192.
43. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781-1790.
44. Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125(3):499-503.
45. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172-183.
46. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441-453.
47. Rea D, Etienne G, Corm S, et al. Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy. Leukemia. 2009;23(6):1193-1196.
48. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358-3363.
49. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-238.